©Author(s) (or their employer(s)) 2026.
World J Gastrointest Surg. Feb 27, 2026; 18(2): 114607
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114607
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114607
Table 5 Incidence of chemotherapy adverse reactions between groups, n (%)
| Adverse reaction | Nutritional risk group (n = 37) | Non-nutritional risk group (n = 43) | P value | ||
| Any grade | ≥ grade 3 | Any grade | ≥ grade 3 | ||
| Hematologic toxicity | |||||
| Leukopenia | 32 (86.5) | 16 (43.2) | 31 (72.1) | 8 (18.6) | 0.015 |
| Neutropenia | 30 (81.1) | 15 (40.5) | 29 (67.4) | 7 (16.3) | 0.012 |
| Thrombocytopenia | 24 (64.9) | 8 (21.6) | 22 (51.2) | 4 (9.3) | 0.127 |
| Anemia | 28 (75.7) | 6 (16.2) | 26 (60.5) | 3 (7.0) | 0.201 |
| Non-hematologic toxicity | |||||
| Nausea and vomiting | 34 (91.9) | 12 (32.4) | 36 (83.7) | 6 (14.0) | 0.042 |
| Diarrhea | 22 (59.5) | 10 (27.0) | 19 (44.2) | 4 (9.3) | 0.039 |
| Mucositis | 18 (48.6) | 5 (13.5) | 15 (34.9) | 2 (4.7) | 0.159 |
| Hand-foot syndrome | 25 (67.6) | 7 (18.9) | 24 (55.8) | 4 (9.3) | 0.221 |
| Peripheral neuropathy | 21 (56.8) | 4 (10.8) | 19 (44.2) | 2 (4.7) | 0.298 |
| Hepatic dysfunction | 16 (43.2) | 3 (8.1) | 13 (30.2) | 1 (2.3) | 0.242 |
| Renal dysfunction | 12 (32.4) | 2 (5.4) | 8 (18.6) | 1 (2.3) | 0.398 |
- Citation: Zhou K, Tu RF, Lu LH, Zhang H. Impact of nutritional status on treatment completion and prognosis during adjuvant chemotherapy following gastric cancer surgery. World J Gastrointest Surg 2026; 18(2): 114607
- URL: https://www.wjgnet.com/1948-9366/full/v18/i2/114607.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i2.114607